IMGN
Price:
$31.235
Market Cap:
$8.73B
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeut...[Read more]
Industry
Biotechnology
IPO Date
1989-11-17
Stock Exchange
NASDAQ
Ticker
IMGN
According to ImmunoGen, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.47. This represents a change of 38.33% compared to the average of 3.95 of the last 4 quarters.
The mean historical Current Ratio of ImmunoGen, Inc. over the last ten years is 3.94. The current 5.47 Current Ratio has changed 13.77% with respect to the historical average. Over the past ten years (40 quarters), IMGN's Current Ratio was at its highest in in the December 2013 quarter at 10.10. The Current Ratio was at its lowest in in the March 2023 quarter at 1.98.
Average
3.94
Median
3.45
Minimum
2.26
Maximum
7.77
Discovering the peaks and valleys of ImmunoGen, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 51.48%
Maximum Annual Current Ratio = 7.77
Minimum Annual Increase = -47.66%
Minimum Annual Current Ratio = 2.26
Year | Current Ratio | Change |
---|---|---|
2022 | 2.26 | 0% |
2021 | 2.26 | -6.01% |
2020 | 2.40 | 5.53% |
2019 | 2.28 | -39.18% |
2018 | 3.74 | -21.84% |
2017 | 4.79 | 51.48% |
2016 | 3.16 | -22.22% |
2016 | 4.06 | -47.66% |
2015 | 7.77 | 16.03% |
2014 | 6.69 | -34.18% |
The current Current Ratio of ImmunoGen, Inc. (IMGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
2.31
5-year avg
2.59
10-year avg
3.94
ImmunoGen, Inc.’s Current Ratio is less than Madrigal Pharmaceuticals, Inc. (5.98), greater than Intercept Pharmaceuticals, Inc. (4.22), greater than TG Therapeutics, Inc. (4.59), less than Terns Pharmaceuticals, Inc. (32.99), greater than Hepion Pharmaceuticals, Inc. (1.30), less than Viking Therapeutics, Inc. (36.47), greater than Axsome Therapeutics, Inc. (2.44), greater than Seres Therapeutics, Inc. (1.12), less than Mereo BioPharma Group plc (6.10), greater than PDS Biotechnology Corporation (2.84), less than Inozyme Pharma, Inc. (7.68), greater than HOOKIPA Pharma Inc. (3.26), greater than eFFECTOR Therapeutics, Inc. (1.03), greater than X4 Pharmaceuticals, Inc. (4.89), less than Elevation Oncology, Inc. (17.77), less than Akero Therapeutics, Inc. (17.25), less than Reata Pharmaceuticals, Inc. (6.75),
Company | Current Ratio | Market cap |
---|---|---|
5.98 | $6.95B | |
4.22 | $794.69M | |
4.59 | $5.27B | |
32.99 | $601.37M | |
1.30 | $4.37M | |
36.47 | $5.71B | |
2.44 | $4.82B | |
1.12 | $139.83M | |
6.10 | $550.85M | |
2.84 | $80.43M | |
7.68 | $172.81M | |
3.26 | $23.94M | |
1.03 | $941.00 | |
4.89 | $65.23M | |
17.77 | $34.16M | |
17.25 | $2.16B | |
6.75 | $6.57B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunoGen, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ImmunoGen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is ImmunoGen, Inc.'s Current Ratio?
How is the Current Ratio calculated for ImmunoGen, Inc. (IMGN)?
What is the highest Current Ratio for ImmunoGen, Inc. (IMGN)?
What is the 3-year average Current Ratio for ImmunoGen, Inc. (IMGN)?
What is the 5-year average Current Ratio for ImmunoGen, Inc. (IMGN)?
How does the current Current Ratio for ImmunoGen, Inc. (IMGN) compare to its historical average?